{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.7","upperLimit":"57.0","value":"46.2"},{"groupId":"OG001","lowerLimit":"38.9","upperLimit":"58.9","value":"49.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"RFS was defined as time from randomization to local/regional recurrence, distant recurrence or death, whichever occurred first. Cases with incomplete follow up or without adequate disease evaluations were censored at the date last documented to be free of RFS events. 3-year RFS rate was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV","id":"OG000","title":"Arm B (Cisplatin or Carboplatin) (Enrolled While Arm C Was Open)"},{"description":"Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO","id":"OG001","title":"Arm C (Capecitabine) (Open to Accrual 6/22/2016)"}],"paramType":"NUMBER","populationDescription":"The primary analysis population was all basal-subtype TNBC patients who were concurrently randomized to arms B and C after 6/22/2016 (intent-to-treat population).","reportingStatus":"POSTED","timeFrame":"No mandatory timeline, assessed at any time as a standard of care procedure or at the investigator's discretion; data reported every 3 months within 2 years from randomization, every 6 months if 2-3 years.","title":"3-year Recurrence-Free Survival (RFS) Rate in Basal-Subtype Patients","type":"SECONDARY","unitOfMeasure":"percentage of participants"}